Melbourne, Nov 7, 2008 (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), is featured today at the 2008 UBS Australian Healthcare Conference underway in Sydney as one of three leading emerging companies in the biotechnology space.
Executive Director Professor Silviu Itescu will update investors on the clinical and commercial progress of Mesoblast's proprietary adult stem cell platform technology, with regard to disorders of bone and cartilage, cardiovascular diseases, eye diseases and bone marrow transplantation.
In addition, he will brief investors on Mesoblast's stem cell business model, with special focus on recent trends in partnering between adult stem cell companies and the global pharmaceutical industry.
The annual UBS Australian Healthcare Conference is the leading healthcare investor conference in Australia.
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.
Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.
The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.
Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.
Mesoblast Limited
